166 related articles for article (PubMed ID: 37775682)
21. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.
Home P; Bartley P; Russell-Jones D; Hanaire-Broutin H; Heeg JE; Abrams P; Landin-Olsson M; Hylleberg B; Lang H; Draeger E;
Diabetes Care; 2004 May; 27(5):1081-7. PubMed ID: 15111525
[TBL] [Abstract][Full Text] [Related]
22. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
[TBL] [Abstract][Full Text] [Related]
23. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus.
Rys P; Wojciechowski P; Rogoz-Sitek A; Niesyczyński G; Lis J; Syta A; Malecki MT
Acta Diabetol; 2015 Aug; 52(4):649-62. PubMed ID: 25585592
[TBL] [Abstract][Full Text] [Related]
24. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.
Standl E; Lang H; Roberts A
Diabetes Technol Ther; 2004 Oct; 6(5):579-88. PubMed ID: 15628811
[TBL] [Abstract][Full Text] [Related]
25. Effects of insulin detemir and NPH insulin on body weight and appetite-regulating brain regions in human type 1 diabetes: a randomized controlled trial.
van Golen LW; Veltman DJ; IJzerman RG; Deijen JB; Heijboer AC; Barkhof F; Drent ML; Diamant M
PLoS One; 2014; 9(4):e94483. PubMed ID: 24739875
[TBL] [Abstract][Full Text] [Related]
26. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.
Bartley PC; Bogoev M; Larsen J; Philotheou A
Diabet Med; 2008 Apr; 25(4):442-9. PubMed ID: 18387078
[TBL] [Abstract][Full Text] [Related]
27. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.
Hermansen K; Fontaine P; Kukolja KK; Peterkova V; Leth G; Gall MA
Diabetologia; 2004 Apr; 47(4):622-9. PubMed ID: 15298338
[TBL] [Abstract][Full Text] [Related]
28. A 26-week, randomized trial of insulin detemir versus NPH insulin in children and adolescents with type 2 diabetes (iDEAt2).
Wheeler MD; Barrientos-Perez M; Lo FS; Liang B; Lunsford A; Thórisdóttir Ó; Zuckerman-Levin N
Eur J Pediatr; 2018 Oct; 177(10):1497-1503. PubMed ID: 30014302
[TBL] [Abstract][Full Text] [Related]
29. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes.
Hermansen K; Davies M; Derezinski T; Martinez Ravn G; Clauson P; Home P
Diabetes Care; 2006 Jun; 29(6):1269-74. PubMed ID: 16732007
[TBL] [Abstract][Full Text] [Related]
30. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the efficacy and safety of insulin glargine and insulin detemir with NPH insulin in children and adolescents with type 1 diabetes mellitus receiving intensive insulin therapy.
Dündar BN; Dündar N; Eren E
J Clin Res Pediatr Endocrinol; 2009; 1(4):181-7. PubMed ID: 21274293
[TBL] [Abstract][Full Text] [Related]
32. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes.
Umpierrez GE; Hor T; Smiley D; Temponi A; Umpierrez D; Ceron M; Munoz C; Newton C; Peng L; Baldwin D
J Clin Endocrinol Metab; 2009 Feb; 94(2):564-9. PubMed ID: 19017758
[TBL] [Abstract][Full Text] [Related]
33. Diabetic pregnancy outcomes in mothers treated with basal insulin lispro protamine suspension or NPH insulin: a multicenter retrospective Italian study.
Dalfrà MG; Soldato A; Moghetti P; Lombardi S; Vinci C; De Cata AP; Romanelli T; Bonomo M; Sciacca L; Tata F; Ragazzi E; Filippi A; Burlina S; Lapolla A
J Matern Fetal Neonatal Med; 2016; 29(7):1061-5. PubMed ID: 25817082
[TBL] [Abstract][Full Text] [Related]
34. Effects of insulin detemir and NPH insulin on renal handling of sodium, fluid retention and weight in type 2 diabetic patients.
Hendriksen KV; Jensen T; Oturai P; Feldt-Rasmussen B
Diabetologia; 2012 Jan; 55(1):46-50. PubMed ID: 22002075
[TBL] [Abstract][Full Text] [Related]
35. Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes: a systematic review and meta-analysis.
Szypowska A; Golicki D; Groele L; Pańkowska E
Pol Arch Med Wewn; 2011; 121(7-8):237-46. PubMed ID: 21878861
[TBL] [Abstract][Full Text] [Related]
36. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A
Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.
Ridderstråle M; Jensen MM; Gjesing RP; Niskanen L
J Med Econ; 2013; 16(4):468-78. PubMed ID: 23384160
[TBL] [Abstract][Full Text] [Related]
38. Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial.
Thalange N; Bereket A; Larsen J; Hiort LC; Peterkova V
Diabet Med; 2013 Feb; 30(2):216-25. PubMed ID: 23094597
[TBL] [Abstract][Full Text] [Related]
39. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
[TBL] [Abstract][Full Text] [Related]
40. A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UK.
Idris I; Gordon J; Tilling C; Vora J
J Med Econ; 2015 Apr; 18(4):273-82. PubMed ID: 25422990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
